@article{e399e278cffe4ee0bcf4212cb5793476,
title = "Phase I trial of \{alpha\}-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML.",
author = "Jurcic, \{Joseph G.\} and Farhad Ravandi and Pagel, \{John M.\} and Park, \{Jae Hong\} and Smith, \{B. Douglas\} and Dan Douer and Levy, \{Moshe Yair\} and Elihu Estey and Kantarjian, \{Hagop M.\} and Dennis Earle and Dragan Cicic and Scheinberg, \{David A.\}",
note = "Background: 225Ac-lintuzumab consists of a radiometal that emits 4 α-particles linked to an anti-CD33 antibody. A phase I trial showed safety and efficacy of 225Ac-lintuzumab in relapsed AML. We are conducting a multicenter, phase I trial to determine the maximum tolerated dose (MTD), toxicity, and activity of fractionated-dose 225Ac-lintuzumab combined with LDAC.",
year = "2015",
month = may,
day = "20",
language = "American English",
volume = "33",
journal = "Journal of Clinical Oncology",
}